Related references
Note: Only part of the references are listed.Mesenchymal Stem Cells Stably Transduced with a Dominant-Negative Inhibitor of CCL2 Greatly Attenuate Bleomycin-Induced Lung Damage
Shigeki Saito et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Mast Cells Are an Essential Component of Human Radiation Proctitis and Contribute to Experimental Colorectal Damage in Mice
Karl Blirando et al.
AMERICAN JOURNAL OF PATHOLOGY (2011)
Selective apoptosis of monocytes and monocyte-derived DCs induced by bortezomib (Velcade)
M. Arpinati et al.
BONE MARROW TRANSPLANTATION (2009)
Prognostic Significance of New Immunohistochemical Markers in Refractory Classical Hodgkin Lymphoma: A Study of 59 Cases
Danielle Canioni et al.
PLOS ONE (2009)
A tense situation: forcing tumour progression
Darci T. Butcher et al.
NATURE REVIEWS CANCER (2009)
Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation
Kai Sun et al.
BLOOD (2008)
Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206
Kristie A. Blum et al.
LEUKEMIA & LYMPHOMA (2007)
Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: results of a prematurely closed phase II study (NCT00148018)
Sven Trelle et al.
HAEMATOLOGICA (2007)
Fibrosis in Hodgkin and non-Hodgkin lymphomas
Canten Tataroglu et al.
PATHOLOGY RESEARCH AND PRACTICE (2007)
Proteasome inhibitors: antitumor effects and beyond
A. Nencioni et al.
LEUKEMIA (2007)
Proteasome inhibition as a new therapeutic principle in hematological malignancies
Constantine S. Mitsiades et al.
CURRENT DRUG TARGETS (2006)
Molecular mechanisms for the release of chemokines from human leukemic mast cell line (HMC)-1 cells activated by SCF and TNF-α:: roles of ERK, p38 MAPK, and NF-κB
CK Wong et al.
ALLERGY (2006)
The Bcl10-Malt1 complex segregates FcεRI-mediated nuclear factor κB activation and cytokine production from mast cell degranulation
S Klemm et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Prostaglandin E-2 promotes degranulation-independent release of MCP-1 from mast cells
T Nakayama et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction
K Takeshita et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
CN Papandreou et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Multistep tumorigenesis and the microenvironment
P Schedin et al.
BREAST CANCER RESEARCH (2004)
IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells
K Kandere-Grzybowska et al.
JOURNAL OF IMMUNOLOGY (2003)
Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma
D Molin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
The role of mast cells in tumour angiogenesis
D Ribatti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease
D Molin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Interleukin-15 prevents mouse mast cell apoptosis through STAT6-mediated Bcl-xL expression
A Masuda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Inflammation and cancer: back to Virchow?
F Balkwill et al.
LANCET (2001)
Preventive and therapeutic vaccines against Helicobacter pylori:: Current status and future challenges
PB Ernst et al.
CURRENT PHARMACEUTICAL DESIGN (2000)
Macrophages and their subpopulations following allogeneic bone marrow transplantation for chronic myeloid leukaemia
J Thiele et al.
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY (2000)